Yao Zhen, Zhao Minyan, Gao Guangyu, Yang Jiawen, Wang Zhenzhen, Liu Yulong
Department of Nuclear Accident Medical Emergency, the Second Affiliated Hospital of Soochow University, Suzhou, China.
Department of Ultrasound, Xingtang Hospital, Suzhou, Jiangsu, People's Republic of China.
Dose Response. 2020 Jun 26;18(2):1559325820931360. doi: 10.1177/1559325820931360. eCollection 2020 Apr-Jun.
In recent years, more and more studies have shown that various inflammatory factors have predictive effects on the prognosis of various human tumors. However, the prognostic role of interleukin 18 (IL-18) remains controversial. Furthermore, its role in radiation-induced injuries relating to radiotherapy (RT) is also unclear. In this study, we conducted the meta-analysis to clarify its roles in prognosis of human tumors and radiation-induced injuries relating to RT.
We comprehensively searched PubMed, Embase, and Cochrane Library to identify studies published before November 2019 involving patients with cancer expressing IL-18 and which reported overall survival (OS) during the follow-up period.
A total of 1376 samples from 16 studies showed that high expression of IL-18 is closely related to prognosis and OS for patients with carcinoma (hazard ratio [HR]: 2.12; 95% CI: 1.81-2.49; .04; random-effect model). In addition, subgroup analysis proved that high expression of IL-18 was related to poor OS of hematologic tumor (HR: 2.03, 95% CI: 1.44-2.86, < .00001), hepatocellular carcinoma (HR: 1.99, 95% CI: 1.38-2.86, = .0002), and gastric cancer (HR: 2.00, 95% CI: 1.12-3.57, = .02).
High expression of IL-18 is related with poor prognosis of carcinoma.
近年来，越来越多的研究表明，各种炎症因子对人类各种肿瘤的预后具有预测作用。然而，白细胞介素18（IL-18）的预后作用仍存在争议。此外，其在放疗（RT）相关的辐射损伤中的作用也不清楚。在本研究中，我们进行了荟萃分析，以阐明其在人类肿瘤预后和RT相关辐射损伤中的作用。
我们全面检索了PubMed、Embase和Cochrane图书馆，以确定2019年11月之前发表的涉及表达IL-18的癌症患者且报告了随访期间总生存期（OS）的研究。
来自16项研究的总共1376个样本表明，IL-18的高表达与癌症患者的预后和OS密切相关（风险比[HR]：2.12；95%置信区间：1.81-2.49；P <.04；随机效应模型）。此外，亚组分析证明，IL-18的高表达与血液系统肿瘤（HR：2.03，95%置信区间：1.44-2.86；P <.00001）、肝细胞癌（HR：1.99,95%置信区间：1.38-2.86；P = 0.0002）和胃癌（HR：2.00,95%置信区间：1.12-3.57；P =0.02）的不良OS相关。
IL-18的高表达与癌症预后不良相关。
